Company intelligence / Profile preview
Brexogen
Seoul, South Koreabrexogen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Brexogen is currently conducting Phase 1 clinical trials for severe atopic dermatitis treatment in the U.S. with their exosome-based therapeutics. They have multiple programs in development, including treatments for myocardial infarction and metabolic diseases requiring regeneration.
- Therapeutic areas
- GastroenterologyCardiovascularDermatologyNephrology
- Modalities
- ExosomesCell-free therapiesStem cell-derived exosomes
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
BMI Korea (technology transfer and licensing agreement signed in February 2025)
Beyond the preview
Go deeper on Brexogen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Brexogen.